SCHEMBL16615830

SCHEMBL16615830

Cc1ncc(CNC(=O)c2ccc(CNS(=O)(=O)c3ccc(Cl)nc3)cn2)s1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRIN2A Q12879 4/20 0.59
GRIN1 Q05586 2/20 0.59
GRIN2B Q13224 1/20 0.53
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
ALDH1A1 P00352 3/20 0.49
PKM P14618 1/20 0.49
CYP2C19 P33261 1/20 0.47
NAMPT P43490 2/20 0.40
CYP2C9 P11712 1/20 0.40
HTT P42858 1/20 0.39
GAA P10253 1/20 0.39
KDM4E B2RXH2 1/20 0.39
TP53 P04637 2/20 0.38
POLB P06746 1/20 0.38
SCD O00767 1/20 0.38
CXCR4 P61073 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16615953 0.89 GRIN2A (0.57) GRIN2AGRIN1GRIN2BMEN1KMT2A
SCHEMBL16615875 0.89 GRIN2A (0.67) GRIN2AGRIN1GRIN2BMEN1KMT2A
SCHEMBL16598092 0.88 GRIN2A (0.61) GRIN2AGRIN1GRIN2BMEN1KMT2A
SCHEMBL16615806 0.88 GRIN2A (0.61) GRIN2AGRIN1GRIN2BMEN1KMT2A
SCHEMBL16615951 0.86 GRIN2A (0.54) GRIN2AGRIN1GRIN2BALDH1A1HTT
SCHEMBL16615882 0.86 GRIN2A (0.69) GRIN2AGRIN1GRIN2BALDH1A1NAMPT
SCHEMBL16598229 0.86 GRIN2A (0.79) GRIN2AGRIN1GRIN2BTP53CXCR4
SCHEMBL16598163 0.86 GRIN2A (0.56) GRIN2AGRIN1GRIN2BALDH1A1NAMPT
SCHEMBL16598435 0.86 GRIN2A (0.61) GRIN2AGRIN1GRIN2BMEN1KMT2A
SCHEMBL16615843 0.86 GRIN2A (0.72) GRIN2AGRIN1GRIN2BKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9963434-B2 N-arylmethyl sulfonamide negative modulators of NR2A LUC THERAPEUTICS, INC. (US) 2018-05-08 US disclosed
US-9963434-B2 N-arylmethyl sulfonamide negative modulators of NR2A LUC THERAPEUTICS, INC. (US) 2018-05-08 US disclosed
US-20160311782-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A NOVARTIS AG (CH) 2016-10-27 US disclosed
US-20160311782-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A NOVARTIS AG (CH) 2016-10-27 US disclosed
US-20150141433-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A MNEMOSYNE PHARMACEUTICALS, INC. 2015-05-21 US disclosed
US-20150141433-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A MNEMOSYNE PHARMACEUTICALS, INC. 2015-05-21 US disclosed
WO-2015048503-A2 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A MNEMOSYNE PHARMACEUTICALS, INC. (US) 2015-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160311782-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A GRIN2A, GRIN2B, NR2C2 GRIN2A 1/4885GRIN1 5/4885GRIN2B 2/4885
US-20150141433-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A GRIN2A, GRIN2B, NR2C2 GRIN2A 1/4885GRIN1 5/4885GRIN2B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.